Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07526428 · ClinicalTrials.gov registry record · NA

Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment

A NA study, sponsored by Sonova.

Terminated
Registry status
NA
Development phase
21
Enrollment target

NCT07526428 is a NA study that was terminated before completion, run by Sonova. The registered enrollment target is 21 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07526428, a NA study, was terminated before completion, sponsored by Sonova.

TERMINATED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when using Phonak's DNN NR feature than when using Competitor device A in a lab setting? Do participants subjectively rate the speech clarity, ease of listening, and listening confidence higher when using Phonak's DNN feature than when using Competitor device A in both a lab setting and a real-world cafe setting? Do participants have an overall preference for the Phonak device over the Competitor device A in a real-world cafe setting? Participants will be fit with both the Phonak device and a Competitor device A in the lab. They will be given the AZBio Sentence test and repeat as many words as they can in a simulated noisy environment. Following the lab visit, participants will meet in a group with three other conversation partners in a real-world setting and asked to complete subjective questionnaires during the visit.

Interventions

  • DEVICE Phonak Audeo Infinio Hearing Aid
  • DEVICE Competitor Device A

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2026-04-09
Est. Completion 2026-04-19
Phase NA

Sponsor

Sonova

29 total trials

What the Registry Record Tells You About NCT07526428

The ClinicalTrials.gov registry entry for NCT07526428 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sonova, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Phonak Audeo Infinio Hearing Aid is the first listed.

NCT07526428 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07526428 about?

NCT07526428 is a clinical study titled "Investigating the DNN Noise Reduction Feature in Phonak Hearing Aids Using Ecological Momentary Assessment". The goal of this interventional study is to evaluate the DNN Noise reduction feature of Phonak hearing aids in adults with moderate to moderate severe hearing loss. The main questions it aims to answer are: Do participants correctly identify significantly more words on the AZBio Sentence Test when ...

What is the current status of trial NCT07526428?

This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2026-04-09. Estimated completion is 2026-04-19.

What interventions are being tested in trial NCT07526428?

The interventions under investigation include: Phonak Audeo Infinio Hearing Aid (DEVICE), Competitor Device A (DEVICE).

Who is sponsoring clinical trial NCT07526428?

This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.